Leerink Partnrs Has Positive Outlook of DexCom Q4 Earnings

DexCom, Inc. (NASDAQ:DXCM) – Investment analysts at Leerink Partnrs lifted their Q4 2024 earnings per share estimates for shares of DexCom in a note issued to investors on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the medical device company will post earnings of $0.49 per share for the quarter, up from their prior estimate of $0.48. The consensus estimate for DexCom’s current full-year earnings is $1.71 per share. Leerink Partnrs also issued estimates for DexCom’s FY2026 earnings at $2.43 EPS, FY2027 earnings at $2.72 EPS and FY2028 earnings at $3.06 EPS.

A number of other analysts have also recently commented on DXCM. Stifel Nicolaus lifted their price target on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd. Royal Bank of Canada lowered their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Raymond James lowered their price target on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Oppenheimer lowered their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, Sanford C. Bernstein lifted their price target on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $104.59.

DexCom Stock Performance

Shares of DXCM opened at $78.10 on Tuesday. The stock has a 50-day moving average of $71.11 and a two-hundred day moving average of $88.51. DexCom has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The stock has a market cap of $30.51 billion, a P/E ratio of 46.77, a P/E/G ratio of 2.38 and a beta of 1.17.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. The trade was a 0.56 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,431 shares of company stock worth $399,319 in the last 90 days. Corporate insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On DexCom

Several large investors have recently bought and sold shares of the company. Kennedy Capital Management LLC purchased a new stake in shares of DexCom in the first quarter valued at approximately $1,690,000. B. Riley Wealth Advisors Inc. grew its position in shares of DexCom by 132.0% in the first quarter. B. Riley Wealth Advisors Inc. now owns 3,766 shares of the medical device company’s stock valued at $522,000 after purchasing an additional 2,143 shares in the last quarter. California State Teachers Retirement System grew its position in shares of DexCom by 0.6% in the first quarter. California State Teachers Retirement System now owns 615,429 shares of the medical device company’s stock valued at $85,360,000 after purchasing an additional 3,500 shares in the last quarter. Motley Fool Asset Management LLC grew its position in shares of DexCom by 6.9% in the first quarter. Motley Fool Asset Management LLC now owns 11,377 shares of the medical device company’s stock valued at $1,578,000 after purchasing an additional 730 shares in the last quarter. Finally, Tidal Investments LLC grew its position in shares of DexCom by 151.8% in the first quarter. Tidal Investments LLC now owns 37,439 shares of the medical device company’s stock valued at $5,193,000 after purchasing an additional 22,572 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.